Fig 1.
Health states include: exacerbation-free, exacerbation states: exacerbation requiring oral corticosteroids, emergency room visit, hospitalizations, and death state.
Table 1.
Model Parameters.
Table 2.
The expected value and 95% CrI of outcomes over a five year time frame.
Fig 2.
(A) Cost-effectiveness plane; (B) Cost-effectiveness acceptability curve; and (C) Expected value of information.
Fig 3.
One-way sensitivity analysis: (A) BT versus standard therapy, (B) omalizumab versus BT.
Fig 4.
Sensitivity analysis for the costs of BT.
Incremental cost-effectiveness ratio as a function of BT’s cost: (A) BT versus standard therapy, (B) omalizumab versus BT.